OBD vs. SAR, HEMO, C4XD, OPTI, SBTX, ONC, DEST, OBI, NSCI, and SNG
Should you be buying Oxford BioDynamics stock or one of its competitors? The main competitors of Oxford BioDynamics include Sareum (SAR), Hemogenyx Pharmaceuticals (HEMO), C4X Discovery (C4XD), OptiBiotix Health (OPTI), SkinBioTherapeutics (SBTX), Oncimmune (ONC), Destiny Pharma (DEST), Ondine Biomedical (OBI), NetScientific (NSCI), and Synairgen (SNG). These companies are all part of the "biotechnology" industry.
Sareum (LON:SAR) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Sareum presently has a consensus price target of GBX 304, indicating a potential upside of 665.74%. Given Oxford BioDynamics' higher probable upside, research analysts clearly believe Sareum is more favorable than Oxford BioDynamics.
Oxford BioDynamics received 22 more outperform votes than Sareum when rated by MarketBeat users. However, 66.13% of users gave Sareum an outperform vote while only 61.90% of users gave Oxford BioDynamics an outperform vote.
In the previous week, Sareum had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for Sareum and 0 mentions for Oxford BioDynamics. Oxford BioDynamics' average media sentiment score of 0.36 beat Sareum's score of 0.00 indicating that Sareum is being referred to more favorably in the media.
36.5% of Oxford BioDynamics shares are held by institutional investors. 4.0% of Sareum shares are held by insiders. Comparatively, 15.7% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Sareum has higher earnings, but lower revenue than Oxford BioDynamics. Sareum is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.
Sareum has a beta of -0.79, meaning that its stock price is 179% less volatile than the S&P 500. Comparatively, Oxford BioDynamics has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.
Sareum's return on equity of -250.52% beat Oxford BioDynamics' return on equity.
Summary
Sareum and Oxford BioDynamics tied by winning 8 of the 16 factors compared between the two stocks.
Get Oxford BioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OBD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford BioDynamics Competitors List
Related Companies and Tools
